Evidence map›Paper›PMID 36430019›Full record

ArticleInternational journal of environmental research and public health2022

Side-Effects following Oxford/AstraZeneca COVID-19 Vaccine in Tororo District, Eastern Uganda: A Cross-Sectional Study.

Jagire Onyango, David Mukunya, Agnes Napyo, Ritah Nantale, Brian T Makoko, Joseph K B Matovu, Benon Wanume, David Okia, Francis Okello, Sam Okware and 2 more

Abstract read
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jagire OnyangoDepartment of Community and Public Health, Busitema University, Mbale P.O. Box 236, Uganda.
David MukunyaDepartment of Community and Public Health, Busitema University, Mbale P.O. Box 236, Uganda.
Agnes NapyoDepartment of Community and Public Health, Busitema University, Mbale P.O. Box 236, Uganda.
Ritah NantaleDepartment of Nursing, Busitema University, Mbale P.O. Box 236, Uganda.
Brian T MakokoDepartment of Community and Public Health, Busitema University, Mbale P.O. Box 236, Uganda.
Joseph K B MatovuDepartment of Community and Public Health, Busitema University, Mbale P.O. Box 236, Uganda.
Benon WanumeDepartment of Community and Public Health, Busitema University, Mbale P.O. Box 236, Uganda.
David OkiaDepartment of Community and Public Health, Busitema University, Mbale P.O. Box 236, Uganda.
Francis OkelloDepartment of Community and Public Health, Busitema University, Mbale P.O. Box 236, Uganda.
Sam OkwareDepartment of Research, Uganda National Health Research Organizations, Kampala P.O. Box 465, Uganda.
Peter Olupot-OlupotDepartment of Community and Public Health, Busitema University, Mbale P.O. Box 236, Uganda.
Yovani LubaaleDepartment of Community and Public Health, Busitema University, Mbale P.O. Box 236, Uganda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effective, safe and proven vaccines would be the most effective strategy against the COVID-19 pandemic but have faced rollout challenges partly due to fear of potential side-effects. We assessed the prevalence, profiles, and predictors of Oxford/AstraZeneca vaccine side-effects in Tororo district of Eastern Uganda. We conducted telephone interviews with 2204 participants between October 2021 and January 2022. Multivariable logistic regression was conducted to assess factors associated with Oxford/AstraZeneca vaccine side-effects using Stata version 15.0. A total of 603/2204 (27.4%) of the participants experienced one or more side-effects (local, systemic, allergic, and other side-effects). Of these, 253/603 (42.0%) experienced local side-effects, 449/603 (74.5%) experienced systemic side-effects, 11/603 (1.8%) experienced allergic reactions, and 166/603 (27.5%) experienced other side-effects. Ten participants declined to receive the second dose because of side-effects they had experienced after the first dose. Previous infection with COVID-19 (adjusted odds ratio (AOR): 4.3, 95% confidence interval (95% CI): 2.7-7.0), being female (AOR: 1.3, 95% CI: 1.1-1.6) and being a security officer (AOR: 0.4, 95% CI: 0.2-0.6) were associated with side-effects to the Oxford/AstraZeneca vaccine. We recommend campaigns to disseminate correct information about potential side-effects of the Oxford/AstraZeneca vaccine and strengthen surveillance for adverse events following vaccination.

Indexed as

COVID-19COVID-19 VaccinesCross-Sectional StudiesFemaleHumansMalePandemicsUgandaCOVID-19 VaccinesCOVID-19Oxford/AstraZeneca vaccineside-effectsUganda

Identifiers

PMID36430019
PMCPMC9690167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.